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Abstract 
 Obsessive-compulsive disorder (OCD) is a potentially impairing mental 
disorder. Even though there are effective treatment approaches, the identification of 
predictors of treatment response can help optimize therapy protocols and apply them 
correctly to each individual case. 
 This paper reviews studies on predictors of treatment response to psychological 
and pharmacological therapies for OCD. Studies were identified through a systematic 
review using the MEDLINE and SCOPUS databases, by searching bibliographies and 
contacting key authors. Search terms included “obsessive-compulsive disorder”, 
“treatment” and “predictors”.  
Forty-one trials reporting association between baseline variables and OCD 
treatment outcome were included. The following factors showed were analyzed for 
potential association with treatment outcome: age at assessment, gender, marital 
status, quality of life, age at onset, OCD severity at onset, family history, length of 
illness, insight, OCD symptom dimensions, comorbid Axis I and II disorders, early 
response to therapy, previous treatment history, therapeutic alliance and treatment 
adherence. Results were inconsistent across most variables in the studied sample, so 
future implications for research and clinical applicability are still very limited. 
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Introduction 
Obsessive-compulsive disorder (OCD) is a brain disorder, characterized by 
recurring obsessions and/or compulsions aimed at reducing the associated anxiety and 
fear, resulting in significant social and functional impairment. Obsessions are defined 
as recurrent and persistent thoughts, urges or images that are experienced as 
unwanted and intrusive, causing anxiety and distress, despite the attempts to ignore, 
neutralize or suppress such thoughts. Compulsions are repetitive behaviors or mental 
acts performed in response to an obsession, with the intent to reduce or neutralize a 
distressing event or situation, usually in an excessive or unrealistic manner (American 
Psychiatric Association, 2013). 
OCD has a lifetime prevalence of approximately 1,6% across all age groups 
and of 0,1-4% in children (Heyman, 2001; Kessler et al., 2005). Onset is usually 
gradual and chronic, with stable symptoms over time, and it is more common in late 
adolescence and early adulthood, with a median age of onset of 19 years (Kessler et 
al., 2005; Mataix-Cols et al., 2002). Comorbid psychological illness is common, 
especially mood and anxiety disorders. Some studies suggest that up to 25% of 
patients with OCD have a current or past history of some form of tic disorder 
(Abramowitz, Taylor, & McKay, 2009; American Psychiatric Association, 2013; Torres 
et al., 2006). 
 Treatment of OCD is effective and can be divided in pharmacological and 
psychological approaches (Abramowitz, 1997). Cognitive-behavioral therapy (CBT), 
including exposure and response prevention (E/RP) is considered the first-line 
treatment for children and adults (Health & Excellence, 2005; March et al., 2004). 
Current evidence suggests that antidepressants, particularly selective serotonin 
reuptake inhibitors (SSRIs) and clomipramine are also effective in the treatment of 
OCD in children and adults (Health & Excellence, 2005). Psychological and 
pharmacological therapies can also be used in combination, in case of severe OCD or 
treatment-resistant OCD. 
 Several treatment outcome studies suggest that certain factors may predict 
poorer or better treatment response and efficacy. The identification of such factors may 
allow the identification of patients at risk of a poorer prognosis, and an individualized 
treatment approach, resulting in better outcomes. Several potential predictors have 
already been identified, but there is limited consensus on which factors really predict a 
different outcome, limiting their appliance in clinical practice. Keeley et al. (2008) 
reviewed predictors of treatment response in open and controlled trials of cognitive-
behavioral therapy for obsessive-compulsive disorder in adults and children, reporting 
several variables consistently associated with outcome, including: strength of the 
therapeutic relationship, patients’ family environment, OCD severity, symptom 
subtypes, comorbid severe depression and comorbid personality disorder (Mary L 
Keeley, Storch, Merlo, & Geffken, 2008). Knopp et al. (2013) systematically reviewed 
the predictors of treatment response to psychological therapies for adults with OCD, 
finding associations between worse treatment outcome and hoarding pathology, 
increased anxiety, OCD severity, symptom subtypes, unemployment and being 
single/not married (Knopp, Knowles, Bee, Lovell, & Bower, 2013). Both reviews 
acknowledge the lack of consensus of their findings, as well as a significant variation in 
the measurement tools and methods across included trials. Given these limitations, the 
present review serves to strengthen currently existing evidence on predictors of 
treatment response to psychological and pharmacological therapies for OCD.  
Methods 
To identify predictors of OCD treatment response, we searched the literature of 
published open and controlled OCD treatment outcome trials of pharmacotherapy, CBT 
or combined therapy in adult or pediatric samples. Articles were identified by a 
systematic electronic literature search on the MEDLINE and SCOPUS databases using 
the keywords “obsessive-compulsive disorder”, “treatment” and “predictors”. Reference 
sections of the studies that emerged in the original search were scanned for additional 
relevant articles and some authors were contacted for full versions of relevant articles 
unobtainable in the original search. Inclusion criteria permitted English language 
clinical trials, with a full-text published at the time of the search. Only studies that 
reported associations between baseline variables and treatment outcome on patients 
with a confirmed diagnosis of OCD were included. Follow-up studies that did not 
involve a standardized therapeutic intervention were excluded.  
All potential predictors of treatment outcome reported in the included articles 
were noted. Potential predictors of outcome were organized in 4 categories: 
demographic characteristics, clinical aspects, comorbidities and treatment specific 
variables. Demographic characteristics include age at assessment, gender, marital 
status and quality of life. Clinical aspects include age at onset, OCD severity at onset, 
family history, length of illness, insight and OCD symptom dimensions. Evaluated 
comorbidities included Axis I and II disorders, as well as specific comorbid mood, 
anxiety or tic disorders and schizotypal and obsessive-compulsive personality 
disorders. Treatment-specific aspects include early response to therapy, previous 
treatment history, therapeutic alliance and treatment adherence. For each included 
predictor, its relationship with outcome was noted, in terms of statistical significance 
and direction (positive, negative or no relationship).  
Results 
The study selection process is detailed in a PRISMA diagram (Fig. 1). Forty-one 
studies were included in this review, with a total of 4670 participants (mean sample 
size = 114; SD = 106.8). Sixteen trials studied isolated pharmacological treatment, 
twenty-five studied psychological therapies and five studied the combined treatment 
approach. Overlap is due to the inclusion of studies with more than one studied 
sample, with different treatment approaches. Thirty-seven studies with adult samples 
and four with pediatric samples were included. Studies varied significantly in regard to 
the study design and the measurement tools used. Treatment interventions were also 
variable in terms of content, duration and intensity. Characteristics of the included 
articles are specified in Table 1. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Characteristics of included studies 
Author Year 
Sample 
size 
Sample 
age group 
Intervention(s) Studied predictors 
Abramowitz 2000 87 Adult CBT Comorbid mood disorder 
Abramowitz 2000 48 Adult CBT Comorbid mood disorder 
Abramowitz 2002 28 Adult CBT Treatment adherence 
Abramowitz 2003 132 Adult CBT OCD symptom subtypes 
Bloch 2009 45 Pediatric Combined therapy 
Age at assessment; Gender; Age at onset; 
OCD severity at onset; Length of illness; 
OCD symptom subtypes; Comorbid mood 
disorder; Comorbid tic disorder 
Bloch 2013 83 Adult Pharmacological 
Age at onset; Length of illness; OCD 
symptom subtypes; Comorbid mood 
disorder; Comorbid anxiety disorder; 
Comorbid tic disorder; Early response to 
therapy 
Boschen 2010 114 Adult CBT 
Age at assessment; Gender; Marital 
status; Age at onset; Length of illness; 
Comorbid mood disorder; Comorbid 
anxiety disorder 
Literature search 
     Databases: PUBMED and SCOPUS 
     Reference sections scanned 
     Authors contacted 
Unique search results combined 
(n=151) 
Unobtainable articles (n=90) 
Articles excluded with reasons (n=20): 
1) Different treatment approach 
(n=1) 
2) Irrelevant study design (no 
standardized therapy/no 
predictors assessed) (n=19) 
Studies included in the analysis 
(n=41) 
Full-text articles assessed (n=61) 
Figure 1. Diagram of study identification and selection 
Table 1. (continued) 
Catapano 2006 79 Adult Pharmacological 
Age at assessment; Gender; Marital 
status; Age at onset; OCD severity at 
onset; Length of illness; Family history; 
Comorbid schizotypal PD; Comorbid 
obsessive-compulsive PD 
Cavedini 1997 30 Adult Pharmacological Comorbid obsessive-compulsive PD 
Cherian 2014 106 Adult Pharmacological Length of illness; Treatment history 
da Conceição 
Costa 
2013 128 Adult Pharmacological Early response to therapy 
Dreessen 1997 52 Adult CBT Comorbid Axis II disorder 
Erzegovesi 2001 159 Adult Pharmacological 
Age at assessment; Gender; Age at onset; 
OCD severity at onset; Length of illness; 
Family history; Insight; OCD symptom 
subtypes; Comorbid mood disorder; 
Comorbid tic disorder; Comorbid 
schizotypal PD; Comorbid obsessive-
compulsive PD 
Fricke 2006 55 Adult CBT Comorbid Axis II disorder 
Garcia 2010 112 Adult 
CBT; 
Pharmacological; 
Combined therapy 
OCD severity at onset; Insight; 
Haan 1997 99 Adult 
CBT; Combined 
therapy 
OCD severity at onset; Comorbid Axis II 
disorder 
Hansen 2007 35 Adult CBT 
Comorbid anxiety disorder; Comorbid Axis 
II disorder 
Jakubovski 2013 196 Adult 
CBT; 
Pharmacotherapy 
Age at onset; Length of illness; Family 
history; OCD symptom subtypes; 
Comorbid mood disorder; Comorbid 
anxiety disorder; Comorbid tic disorder; 
Early response to therapy 
Keeley 2011 25 Pediatric CBT Therapeutic alliance 
Kim 2011 249 Adult Pharmacological 
Age at assessment; Gender; Age at onset; 
OCD severity at onset; Length of illness; 
Family history; Insight; Comorbid mood 
disorder; Comorbid tic disorder; Comorbid 
Axis II disorder; Treatment history 
Landeros-
Weisenberger 
2010 165 Adult Pharmacological OCD symptom subtypes 
Langner 2009 154 Adult CBT 
Age at assessment; Gender; Marital 
status; Age at onset; Length of illness 
Maher 2010 108 Adult Combined therapy 
Quality of life; OCD severity at onset; 
Insight; Hoarding symptom subtype; 
Comorbid Axis I disorders; Comorbid Axis 
II disorder; 
Table 1. (continued) 
Maher 2012 28 Adult CBT 
Hoarding symptom subtype; Therapeutic 
alliance; Treatment adherence 
Mataix-Cols 1999 150 Adult Pharmacological OCD symptom subtypes 
Moritz 2004 53 Adult CBT 
Age at assessment; Gender; Age at onset; 
Length of illness; Schyzotypal PD 
Mundo 1999 50 Adult Pharmacological 
Age at assessment; Gender; Age at onset; 
Length of illness; Family history; Comorbid 
tic disorder 
Piacentini 2002 42 Pediatric CBT 
Age at assessment; Gender; OCD severity 
at onset; Comorbid tic disorder 
Pinto 2011 49 Adult CBT Obsessive-compulsive PD 
Raffin 2009 181 Adult CBT 
Age at assessment; Gender; Marital 
status; Quality of life; Age at onset; OCD 
severity at onset; Length of illness; Family 
history; Insight; Comorbid anxiety disorder 
Rufer 2006 104 Adult CBT OCD symptom subtypes 
Shavitt 2006 41 Adult Pharmacological 
Gender; Age at onset; Length of illness; 
Family history; Comorbid tic disorder; 
Treatment history 
Simpson 2011 30 Adult CBT 
Hoarding symptom subtype; Treatment 
adherence 
Stein 2001 401 Adult Pharmacological 
Age at assessment; Gender; OCD severity 
at onset; Length of illness; Treatment 
history 
Stein 2007 434 Adult Pharmacological OCD symptom subtypes 
Steketee 2001 63 Adult CBT 
Comorbid mood disorder; Comorbid 
anxiety disorder, Comorbid Axis II disorder 
Steketee 2011 39 Adult CBT 
OCD severity at onset; OCD symptom 
dimensions; Comorbid Axis I disorder 
Stewart 2006 476 Adult 
Combined therapy 
(IRT) Gender; Comorbid tic disorder 
Storch 2006 60 Adult Pharmacological 
Age at assessment; Gender; Age at onset; 
OCD severity at onset; Length of illness; 
Comorbid mood disorder; Comorbid tic 
disorder; Treatment history 
Storch 2010 143 Adult CBT 
Comorbid mood disorder; Comorbid 
anxiety disorder 
Vogel 2006 37 Adult CBT Therapeutic alliance 
Note: CBT = cognitive behavior therapy; OCD = obsessive-compulsive disorder; PD = personality disorder 
 
 
Demographic characteristics 
Across ten studies, current age was not predictive of treatment response. These 
included eight adult and two pediatric samples and studied pharmacological, 
psychological and combined treatments (Bloch et al., 2009; Boschen, Drummond, 
Pillay, & Morton, 2010; Catapano et al., 2006; Erzegovesi et al., 2001; Kim et al., 2011; 
Moritz et al., 2004; Mundo, Bareggi, Pirola, & Bellodi, 1999; Piacentini, Bergman, 
Jacobs, McCracken, & Kretchman, 2002; Raffin, Guimaraes Fachel, Ferrao, Pasquoto 
de Souza, & Cordioli, 2009; D. Stein, Montgomery, Kasper, & Tanghoj, 2001). 
However, one trial (Langner et al., 2009) found that older age was associated with poor 
response to CBT, and one fluoxetine trial (Storch et al., 2006) found an association 
between older age and failure of treatment. 
Fourteen studies investigated the effect of gender on treatment response. Three 
adult studies found an association between female gender and better treatment 
response. Raffin et al. (2009) reported this association for CBT, Mundo et al. (1999) for 
a Clomipramine trial and Stewart et al. (2006) for a combined approach for adults with 
severe OCD in intensive residential treatment. Eleven trials, including two pediatric 
studies, failed to find any association between gender and treatment response (Bloch 
et al., 2009; Boschen et al., 2010; Catapano et al., 2006; Erzegovesi et al., 2001; Kim 
et al., 2011; Langner et al., 2009; Moritz et al., 2004; Piacentini et al., 2002; Shavitt et 
al., 2006; D. Stein et al., 2001; Storch et al., 2006). 
Of the four studies assessing the influence of marital status on treatment 
outcome, two found no significant association (Catapano et al., 2006; Raffin et al., 
2009). However, Boschen and colleagues (2010) reported a better treatment response 
to CBT in married patients as compared to single, divorced or separated 
patients(Boschen et al., 2010). Langer et al. (2009) also found that being in a stable 
relationship (being married or living with a partner for ≥3 years) predicted better 
treatment outcome for patients with late-onset OCD. 
A lower quality of life before treatment predicted a worse outcome in both a 
CBT trial and a combined treatment trial in adults (Maher et al., 2010; Raffin et al., 
2009). 
Clinical aspects 
 In ten adult and one pediatric trials, age of onset of OCD was not predictive of 
treatment response (Bloch et al., 2009; Bloch et al., 2013; Boschen et al., 2010; 
Catapano et al., 2006; Kim et al., 2011; Langner et al., 2009; Moritz et al., 2004; Mundo 
et al., 1999; Raffin et al., 2009; Shavitt et al., 2006; Storch et al., 2006). The exceptions 
to this trend in the adult literature were Erzegovesi et al. (2001) and Jakubovski et al. 
(2013), who reported early onset as a predictor of worse outcome. 
 OCD symptom severity at onset, measured using the Yale-Brown Obsessive-
Compulsive Scale (Y-BOCS), was consistently associated with a worse treatment 
response, across all treatment conditions, in adult and pediatric samples (Bloch et al., 
2009; Catapano et al., 2006; Garcia et al., 2010; Haan et al., 1997; Kim et al., 2011; 
Maher et al., 2010; Piacentini et al., 2002; Raffin et al., 2009; D. Stein et al., 2001; 
Steketee et al., 2011; Storch et al., 2006). Only one trial failed to find a significant effect 
of severity at onset (Erzegovesi et al., 2001). 
The length of illness was studied in fourteen adult and one pediatric trials. 
Longer duration of disease predicted worse outcome in three pharmacological 
treatment trials (Catapano et al., 2006; D. Stein et al., 2001; Storch et al., 2006) and in 
a combined approach trial (Jakubovski et al., 2013). Jakubovski et al. (2013) found that 
early onset of OCD is interconnected with length of illness, and suggested that their 
effects on treatment outcome may be related and require further investigation. In the 
rest of the studies, length of illness did not predict treatment response for different 
treatment approaches (Bloch et al., 2009; Bloch et al., 2013; Boschen et al., 2010; 
Cherian, Math, Kandavel, & Reddy, 2014; Erzegovesi et al., 2001; Kim et al., 2011; 
Langner et al., 2009; Moritz et al., 2004; Mundo et al., 1999; Raffin et al., 2009; Shavitt 
et al., 2006). 
Erzegovesi et al. (2001) reported a significant higher frequency of family history 
of OCD in first degree relatives among responders to a standardized pharmacological 
treatment. Jakubovski et al. (2013) found an association between worse treatment 
response in both CBT and pharmacological treatment samples and a family history of 
tics or anxiety disorders. This association wasn’t significant for family history of OCD. In 
five other trials, family history of OCD was not a significant predictor of response to 
treatment (Catapano et al., 2006; Kim et al., 2011; Mundo et al., 1999; Raffin et al., 
2009; Shavitt et al., 2006). 
One study found a significant association between insight and response to CBT 
in adults (Raffin et al., 2009), while another trial found that patients with poor insight 
responded worse to pharmacological treatment (Erzegovesi et al., 2001). Garcia et al. 
(2010) reported a similar result in a pediatric sample, with patients with greater insight 
showing better improvement across all treatment categories. Two other studies with 
adult samples did not find any significant association between insight and treatment 
response (Kim et al., 2011; Maher et al., 2010). 
The heterogeneity of OCD symptoms allows it to be split into different subtypes, 
which have been studied as possible predictors of treatment outcome. Three adult 
trials comparing hoarding, sexual/religious obsessions, contamination/cleaning, 
aggression/checking and symmetry/order subtypes found no evidence of a significant 
association between symptom dimensions and treatment response for pharmacological 
therapy and CBT (Bloch et al., 2013; Erzegovesi et al., 2001; Jakubovski et al., 2013). 
However, several other studies consistently show that the hoarding subtype is a 
predictor of poorer outcome, for both pharmacological and psychological treatment 
approaches (Abramowitz, Franklin, Schwartz, & Furr, 2003; Maher et al., 2012; Mataix-
Cols, Rauch, Manzo, Jenike, & Baer, 1999; Rufer, Fricke, Moritz, Kloss, & Hand, 2006; 
Simpson et al., 2011; D. J. Stein, Andersen, & Overo, 2007). One study reported that 
aggressive symptoms were associated with a better pharmacological treatment 
response. In this study, the hoarding subtype showed the highest percentage of non-
responders, but the number of patients was insufficient to assess this dimension 
statistically (Landeros-Weisenberger et al., 2010). Steketee et al. (2011) reported that 
the presence of sexual OCD symptoms, but not religious, predicted a favorable 
treatment response to CBT. In one study using a pediatric sample, hoarding subtype 
was reported as a negative predictor of treatment outcome (Bloch et al., 2009). 
Comorbidities 
 Three trials studied the influence of comorbid Axis I disorders on outcome in 
adult samples, with conflicting results. Steketee at al. (2011) found that Axis I 
comorbidities predicted greater improvement in a sample receiving CBT. On the other 
hand, Maher et al. (2013) and Jakubovski et al. (2013) reported a poorer outcome for 
patients ongoing combiner therapy for OCD with comorbid Axis I disorders.  
 Several other trials studied specific disorders and their effect on treatment 
response. Jakubovski et al. (2013), Steketee et al. (2000) and Abramowitz et al. (2001) 
found that comorbid Major Depressive Disorder (MDD) predicted poorer response to 
CBT. In another study, Abramowitz et al. (2000) also found that depression severity 
predicted worse CBT outcome, by dividing the sample in non-depressed and mildly, 
moderately and severely depressed groups and comparing post-treatment scores 
(Abramowitz, Franklin, Street, Kozak, & Foa, 2000). Five other adult studies and one 
pediatric study did not find depression and other mood disorders to be predictive of 
treatment response across all treatment conditions (Bloch et al., 2009; Bloch et al., 
2013; Boschen et al., 2010; Erzegovesi et al., 2001; Kim et al., 2011; Storch et al., 
2006). 
 Most studies assessing comorbid anxiety disorders found no significant 
association between these and treatment outcome for CBT (Boschen et al., 2010; 
Jakubovski et al., 2013; Raffin et al., 2009; Steketee, Chambless, & Tran, 2001; Storch 
et al., 2010) or pharmacological treatment (Bloch et al., 2013; Jakubovski et al., 2013) 
in adults. One exception in the literature is Hansen et al. (2007) - that reported poorer 
treatment response for patients with comorbid generalized anxiety disorder (GAD) 
and/or panic disorder in an adult sample receiving CBT (Hansen, Vogel, Stiles, & 
Gotestam, 2007). 
 Despite the high rate of comorbid tic disorder in pediatric OCD, Piacentini et al. 
(2002) found that these do not predict response to CBT. In one other pediatric study, 
Bloch et al. (2009) reported that patients with comorbid chronic tic disorder (CTD) 
showed earlier OCD symptom remission after a combined treatment approach, and 
also had a higher rate of remission by adulthood. In adult samples, most studies did not 
find any significant effect of comorbid tic disorders on pharmacological treatment 
response (Bloch et al., 2013; Erzegovesi et al., 2001; Jakubovski et al., 2013; Kim et 
al., 2011; Mundo et al., 1999; Shavitt et al., 2006; Storch et al., 2006). However, 
Stewart et al. (2006) reported that patients who responded to intensive residential 
combined treatment had a significantly lower rate of comorbid tic disorders (Stewart, 
Yen, Stack, & Jenike, 2006). 
 The presence of comorbid Axis II disorders predicted a poorer treatment 
outcome in two CBT trials, across all clusters of personality disorders (Hansen et al., 
2007; Steketee et al., 2001). Five other trials failed to find any association between 
Axis II comorbidities and treatment response (Dreessen, Hoekstra, & Arntz, 1997; 
Fricke et al., 2006; Haan et al., 1997; Kim et al., 2011; Maher et al., 2010). However, in 
one of these trials, Fricke et al. (2006) reported a trend towards significance for poorer 
treatment response in patients with a comorbid personality disorder, and found that 
these patients had a significantly longer duration of illness. Specific personality 
disorders have also been studied to some extent. Schizotypal symptoms predicted 
worse outcome in a CBT trial (Moritz et al., 2004), however Catapano et al. (2006) and 
Erzegovesi et al. (2001) found that schizotypal personality disorder did not predict 
response to pharmacological treatment. Two studies reported an association between 
obsessive-compulsive personality disorder and poor response to pharmacological 
treatment (Catapano et al., 2006; Cavedini, Erzegovesi, Ronchi, & Bellodi, 1997). One 
trial found a similar association between obsessive-compulsive personality disorder 
and CBT response (Pinto, Liebowitz, Foa, & Simpson, 2011). Only Erzegovesi et al. 
(2001) found that obsessive-compulsive personality disorder did not predict treatment 
response for pharmacological treatment.  
Treatment-specific variables 
Three studies assessed the influence of early response to pharmacological 
treatment on long-term outcome in adults. All of them reported that an improved initial 
response predicts a better outcome (Bloch et al., 2013; da Conceição Costa et al., 
2013; Jakubovski et al., 2013).  Jakubovski et al. (2013) also reported that initial 
response correlated positively with long-term response in a sample ongoing fluoxetine 
treatment but not in a CBT sample. These results may have important implications for 
treatment strategies, allowing the earlier implementation of an alternative therapy in 
case of failure of the initial intervention.  
Treatment history was studied in five trials of pharmacotherapy in adults. Three 
studies reported that patients who had been previously treated with a pharmacological 
intervention were less likely to respond to therapy as opposed to drug-naïve patients 
(Cherian et al., 2014; Kim et al., 2011; D. Stein et al., 2001). Storch et al. (2006) and 
Shavitt et al. (2006) also studied this relation but failed to find any significant results.  
Therapeutic alliance positively predicted treatment outcome in two adult and 
one pediatric trials of CBT (M. L. Keeley, Geffken, Ricketts, McNamara, & Storch, 
2011; Maher et al., 2012; Vogel, Hansen, Stiles, & Gotestam, 2006). In one of these 
studies, therapeutic alliance showed a significant correlation with treatment response in 
a post-treatment analysis, but not on a 12 month follow-up analysis, showing however, 
a trend towards significance (Vogel et al., 2006). Maher et al. (2012) reported that the 
effect of the therapeutic alliance on treatment outcome was mediated by its effect on 
treatment adherence. Treatment adherence was significantly associated with a better 
treatment outcome in three adult CBT trials (Abramowitz, Franklin, Zoellner, & 
Dibernardo, 2002; Maher et al., 2012; Simpson et al., 2011). 
Discussion 
 Overall, solid evidence regarding predictors of treatment response in obsessive-
compulsive disorder is still lacking. Even though we found a significant number of trials 
reporting on the relationship between demographical variables and OCD treatment 
outcome, the results were mostly inconsistent. Younger age, female gender and marital 
status predicted a better outcome in a minority of the studies, however most evidence 
failed to support this association. Quality of life positively associated with treatment 
response, but it was evaluated in two studies only. 
The studies we found on clinical variables also presented varying results, 
regarding the effect of age at onset, length of illness and family history of OCD on 
treatment outcome. More consistent findings were reported on the OCD severity at 
onset and insight variables, which were found to be predictors of a worse and better 
response, respectively, across most studies of our sample. The analysis of OCD 
symptom subtypes also shows a trend towards a worse treatment response for the 
hoarding subtype. Regarding comorbid disorders, gathered evidence varies greatly 
between non-significance and worse outcome across all conditions. In the studies we 
were able to gather, depression and personality disorders were more often associated 
with poorer treatment response than other comorbid disorders. The treatment-specific 
variables category provided the most consistent results, since in our sample early 
treatment response, being treatment-naïve, a good therapeutic alliance and treatment 
adherence all predicted a better outcome for OCD treatment. 
 Although evidence is still less than optimal, it has important implications for 
future research and clinical practice. In light of the differences in treatment response for 
OCD symptom subtypes, particularly for the hoarding subtype, further research should 
focus on identifying and implementing specific and personalized treatments for this 
group of patients. Alternative treatments, such as monoamine oxidase inhibitors 
(MAOI) or deep brain stimulation (DBS) have been proposed but still require more 
extensive examination (Mataix-Cols et al., 1999; Sedrak et al., 2013; D. J. Stein et al., 
2007). A tailored strategy for cognitive behavioral therapies directed at hoarding 
symptoms may also improve outcome. Techniques focused on improving patient’s 
adherence, insight into the need to discard possessions, reducing excessive emotional 
attachment to items and increasing ability to categorize possessions, are examples of 
specific approaches to this subtype (Abramowitz et al., 2003; Mary L Keeley et al., 
2008; Maher et al., 2012; Mataix-Cols et al., 1999). 
The finding that depression is predictive of a worse outcome may also justify a 
different methodology. Authors propose that patients with comorbid depression may 
not benefit fully from treatment and/or have compromised treatment adherence 
(Abramowitz & Foa, 2000; Abramowitz et al., 2000; Jakubovski et al., 2013). Treating 
depressive symptoms before treatment for OCD or psychological treatment 
augmentation with antidepressant medication are examples of proposed strategies for 
this patient group. Similar implications can be found for comorbid personality disorders. 
Authors hypothesize that patients with OCD with a comorbid personality disorder may 
benefit form tailored therapies aimed at specific personality traits or symptoms. As an 
example, Fricke at al. (2006) propose low-dose atypical neuroleptics or specific 
psychotherapy modules aimed at positive schizotypal symptoms for patients with 
schizotypal personality traits.  
 The study of treatment-specific variables and their relation to treatment 
response yielded consistent results and some conclusions can be taken from their 
analysis. Since an early treatment response predicted a better outcome on a long-term 
follow-up, an alternative therapeutic approach should be considered in case of failure 
of the first method. Drug-naïve patients showed improved results compared to patients 
with a history of pharmacological treatment, therefore authors hypothesize that 
ineffective anti-obsessive medication may decrease the effect of further 
pharmacological therapies and an alternative approach may be a better option (Kim et 
al., 2011). Strategies to enhance treatment compliance and specific therapist attributes 
and techniques than improve therapeutic alliance should be researched and 
developed, since these variables predict a positive response to treatment (M. L. Keeley 
et al., 2011; Maher et al., 2012). 
 Several limitations of this article should be noted. The article identification and 
selection process was far from optimal due to the unfunded nature of this review, since 
a great number of potential studies were excluded due to the need for a paid 
subscription to the respective publications, resulting in a very large number of 
“unobtainable” articles. Another important limitation is the heterogeneity of study design 
in the selected articles, which differed in regard to evaluated predictors, predictor and 
outcome measures, definitions of treatment response, inclusion and exclusion criteria 
and follow-up period. The studied interventions also varied greatly in terms of type, 
intensity, and content. As for the chosen analysis method, the classification based on 
statistical significance and effect direction does not consider a quantitative effect of the 
studied predictors, which would translate the magnitude of their effect on treatment 
outcome. Finally, the analysis of the results is greatly hindered by the inconsistent 
results found, making it difficult to make recommendations for future research and 
clinical practice. 
Conclusions 
While there is a growing number on studies focused on predictors of treatment 
response in OCD, representing a great interest on their possible application in clinical 
practice, findings are still very inconsistent. Future research should focus on expanding 
the known scope of possible predictors, as well as understanding possible moderators 
and mediators of their effect. Standardized and uniform study designs are necessary to 
assure high quality literature. In line with previous reviews, we conclude that based on 
the results of current and further research, knowledge on predictors of OCD treatment 
outcome should ultimately be applied to clinical practice through the development of 
tailored and specific treatment approaches (Mary L Keeley et al., 2008; Knopp et al., 
2013). 
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searches and provided summaries of previous research studies. Author D conducted the statistical
analysis. Author B wrote the first draft of the manuscript and all authors contributed to and have
approved the final manuscript.
Statement 3: Conflict of Interest
All authors must disclose any actual or potential conflict of interest. Conflict of interest is defined
as any financial or personal relationships with individuals or organizations, occurring within three
(3) years of beginning the submitted work, which could inappropriately influence, or be perceived
to have influenced the submitted research manuscript. Potential conflict of interest would include
employment, consultancies, stock ownership (except personal investments equal to the lesser of one
percent (1%) of total personal investments or USD$5000), honoraria, paid expert testimony, patent
applications, registrations, and grants. If there are no conflicts of interest by any author, it should
state that there are none.
Example: Author B is a paid consultant for XYZ pharmaceutical company. All other authors declare
that they have no conflicts of interest.
Statement 4: Acknowledgements (optional)
Authors may provide Acknowledgments which will be published in a separate section along with the
manuscript. If there are no Acknowledgements, there should be no heading or acknowledgement
statement.
Example: The authors wish to thank Ms. A who assisted in the proof-reading of the manuscript.
AUTHOR INFORMATION PACK 13 Feb 2014 www.elsevier.com/locate/jocrd 7
Use of word processing software
Regardless of the file format of the original submission, at revision you must provide us with an
editable file of the entire article. Keep the layout of the text as simple as possible. Most formatting
codes will be removed and replaced on processing the article. The electronic text should be prepared in
a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier:
http://www.elsevier.com/guidepublication). See also the section on Electronic artwork.
To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check'
functions of your word processor.
Article structure
Introduction
State the objectives of the work and provide an adequate background, avoiding a detailed literature
survey or a summary of the results. If the focus of the paper is on a disorder other than OCD (as
defined in DSM-IV.TR), provide a rationale for including the disorder as an obsessive-compulsive
related disorder (see Editorial Guidance section).
Methods
Provide sufficient detail to allow the work to be reproduced. Methods already published should be
indicated by a reference: only relevant modifications should be described.
Theory/calculation
A Theory section should extend, not repeat, the background to the article already dealt with in the
Introduction and lay the foundation for further work. In contrast, a Calculation section represents a
practical development from a theoretical basis.
Results
Results should be clear and concise.
Discussion
This should explore the significance of the results of the work, not repeat them. Avoid extensive
citations and discussion of published literature. Be sure to include limitations of the present study
and suggestions for future research.
Conclusions
The main conclusions of the study may be presented in a short Conclusions section, which may stand
alone or form a subsection of a Discussion or Results and Discussion section.
Appendices
If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations in
appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a subsequent appendix,
Eq. (B.1) and so on. Similarly for tables and figures: Table A.1; Fig. A.1, etc.
Clinical reports and case histories
The Journal will consider clinical reports that articulate the treatment of OCD or related disorders using
any theoretical framework (biological, behavioral, cognitive, gestalt, humanistic, psychodynamic, and
others). Clinical reports should use the following format (maximum manuscript length is 30 pages
in total):
1. Theoretical and Research Basis for the Treatment
2. Case Introduction (presenting complaints, history, etc.)
3. Assessment (what instruments were used [and justification if needed])
4. Case Conceptualization (discuss the clinician's thinking about the case and the treatment selection)
5. Course of Treatment and Assessment of Progress (Describe what happened during treatment
and the outcome at post-treatment and follow up. If possible, use single case research design
methodology; see Barlow, Nock, &Hersen [2009])
6. Complicating Factors (if any, including medical management)
7. Treatment Implications of the Case
8. Recommendations to Clinicians and Students
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Shorter communications/Brief reports
This option is designed to allow publication of research reports that are not suitable for publication as
regular articles. Shorter Communications or Brief Reports are appropriate for articles with a specialized
focus or of particular didactic value. Manuscripts should be between 3000-5000 words, and must not
exceed the upper word limit. This limit includes the abstract, text, and references, but not the title
page, tables and figures.
Essential title page information
• Title. Concise and informative. Titles are often used in information-retrieval systems. Avoid
abbreviations and formulae where possible.
• Author names and affiliations. Where the family name may be ambiguous (e.g., a double name),
please indicate this clearly. Present the authors' affiliation addresses (where the actual work was
done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after
the author's name and in front of the appropriate address. Provide the full postal address of each
affiliation, including the country name and, if available, the e-mail address of each author.
• Corresponding author. Clearly indicate who will handle correspondence at all stages of refereeing
and publication, also post-publication. Ensure that phone numbers (with country and area
code) are provided in addition to the e-mail address and the complete postal address.
Contact details must be kept up to date by the corresponding author.
• Present/permanent address. If an author has moved since the work described in the article was
done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as
a footnote to that author's name. The address at which the author actually did the work must be
retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.
Abstract
A concise and factual abstract is required. The abstract should state briefly the purpose of the
research, the principal results and major conclusions. An abstract is often presented separately from
the article, so it must be able to stand alone. For this reason, References should be avoided, but if
essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should
be avoided, but if essential they must be defined at their first mention in the abstract itself.
Graphical abstract
A Graphical abstract is optional and should summarize the contents of the article in a concise, pictorial
form designed to capture the attention of a wide readership online. Authors must provide images
that clearly represent the work described in the article. Graphical abstracts should be submitted as a
separate file in the online submission system. Image size: Please provide an image with a minimum
of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 ×
13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office
files. See http://www.elsevier.com/graphicalabstracts for examples.
Authors can make use of Elsevier's Illustration and Enhancement service to ensure the best
presentation of their images also in accordance with all technical requirements: Illustration Service.
Highlights
Highlights are a short collection of bullet points that convey the core findings of the article. Highlights
are optional and should be submitted in a separate file in the online submission system. Please use
'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces,
per bullet point). See http://www.elsevier.com/highlights for examples.
Keywords
Immediately after the abstract, provide a maximum of 6 keywords, using American spelling and
avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing
with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords
will be used for indexing purposes.
Acknowledgements
Collate acknowledgements in a separate section at the end of the article before the references and do
not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those
individuals who provided help during the research (e.g., providing language help, writing assistance
or proof reading the article, etc.).
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Math formulae
Present simple formulae in the line of normal text where possible and use the solidus (/) instead of
a horizontal line for small fractional terms, e.g., X/Y. In principle, variables are to be presented in
italics. Powers of e are often more conveniently denoted by exp. Number consecutively any equations
that have to be displayed separately from the text (if referred to explicitly in the text).
Footnotes
Footnotes should be used sparingly. Number them consecutively throughout the article. Many
wordprocessors build footnotes into the text, and this feature may be used. Should this not be the
case, indicate the position of footnotes in the text and present the footnotes themselves separately
at the end of the article. Do not include footnotes in the Reference list.
Table footnotes
Indicate each footnote in a table with a superscript lowercase letter.
Artwork
Electronic artwork
General points
• Make sure you use uniform lettering and sizing of your original artwork.
• Preferred fonts: Arial (or Helvetica), Times New Roman (or Times), Symbol, Courier.
• Number the illustrations according to their sequence in the text.
• Use a logical naming convention for your artwork files.
• Indicate per figure if it is a single, 1.5 or 2-column fitting image.
• For Word submissions only, you may still provide figures and their captions, and tables within a
single file at the revision stage.
• Please note that individual figure files larger than 10 MB must be provided in separate source files.
A detailed guide on electronic artwork is available on our website:
http://www.elsevier.com/artworkinstructions.
You are urged to visit this site; some excerpts from the detailed information are given here.
Formats
Regardless of the application used, when your electronic artwork is finalized, please 'save as' or
convert the images to one of the following formats (note the resolution requirements for line drawings,
halftones, and line/halftone combinations given below):
EPS (or PDF): Vector drawings. Embed the font or save the text as 'graphics'.
TIFF (or JPG): Color or grayscale photographs (halftones): always use a minimum of 300 dpi.
TIFF (or JPG): Bitmapped line drawings: use a minimum of 1000 dpi.
TIFF (or JPG): Combinations bitmapped line/half-tone (color or grayscale): a minimum of 500 dpi
is required.
Please do not:
• Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); the resolution is too low.
• Supply files that are too low in resolution.
• Submit graphics that are disproportionately large for the content.
Color artwork
Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or
MS Office files) and with the correct resolution. If, together with your accepted article, you submit
usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in
color on the Web (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations
are reproduced in color in the printed version. For color reproduction in print, you will receive
information regarding the costs from Elsevier after receipt of your accepted article. Please
indicate your preference for color: in print or on the Web only. For further information on the
preparation of electronic artwork, please see http://www.elsevier.com/artworkinstructions.
Please note: Because of technical complications which can arise by converting color figures to 'gray
scale' (for the printed version should you not opt for color in print) please submit in addition usable
black and white versions of all the color illustrations.
Figure captions
Ensure that each illustration has a caption. A caption should comprise a brief title (not on the figure
itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but
explain all symbols and abbreviations used.
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Tables
Number tables consecutively in accordance with their appearance in the text. Place footnotes to tables
below the table body and indicate them with superscript lowercase letters. Avoid vertical rules. Be
sparing in the use of tables and ensure that the data presented in tables do not duplicate results
described elsewhere in the article.
References
Citation in text
Please ensure that every reference cited in the text is also present in the reference list (and vice
versa). Any references cited in the abstract must be given in full. Unpublished results and personal
communications are not recommended in the reference list, but may be mentioned in the text. If these
references are included in the reference list they should follow the standard reference style of the
journal and should include a substitution of the publication date with either 'Unpublished results' or
'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted
for publication.
Web references
As a minimum, the full URL should be given and the date when the reference was last accessed. Any
further information, if known (DOI, author names, dates, reference to a source publication, etc.),
should also be given. Web references can be listed separately (e.g., after the reference list) under a
different heading if desired, or can be included in the reference list.
References in a special issue
Please ensure that the words 'this issue' are added to any references in the list (and any citations in
the text) to other articles in the same Special Issue.
Reference formatting
There are no strict requirements on reference formatting at submission. References can be in any style
or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book
title, chapter title/article title, year of publication, volume number/book chapter and the pagination
must be present. Use of DOI is highly encouraged. The reference style used by the journal will be
applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted
at proof stage for the author to correct. If you do wish to format the references yourself they should
be arranged according to the following examples:
Reference style
Text: Citations in the text should follow the referencing style used by the American
Psychological Association. You are referred to the Publication Manual of the American Psychological
Association, Sixth Edition, ISBN 978-1-4338-0561-5, copies of which may be ordered from
http://books.apa.org/books.cfm?id=4200067 or APA Order Dept., P.O.B. 2710, Hyattsville, MD
20784, USA or APA, 3 Henrietta Street, London, WC3E 8LU, UK.
List: references should be arranged first alphabetically and then further sorted chronologically if
necessary. More than one reference from the same author(s) in the same year must be identified by
the letters 'a', 'b', 'c', etc., placed after the year of publication.
Examples:
Reference to a journal publication:
Van der Geer, J., Hanraads, J. A. J., & Lupton, R. A. (2010). The art of writing a scientific article.
Journal of Scientific Communications, 163, 51–59.
Reference to a book:
Strunk, W., Jr., & White, E. B. (2000). The elements of style. (4th ed.). New York: Longman, (Chapter
4).
Reference to a chapter in an edited book:
Mettam, G. R., & Adams, L. B. (2009). How to prepare an electronic version of your article. In B. S.
Jones, & R. Z. Smith (Eds.), Introduction to the electronic age (pp. 281–304). New York: E-Publishing
Inc.
Journal abbreviations source
Journal names should be abbreviated according to the List of Title Word Abbreviations:
http://www.issn.org/2-22661-LTWA-online.php.
Video data
Elsevier accepts video material and animation sequences to support and enhance your scientific
research. Authors who have video or animation files that they wish to submit with their article are
strongly encouraged to include links to these within the body of the article. This can be done in the
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same way as a figure or table by referring to the video or animation content and noting in the body
text where it should be placed. All submitted files should be properly labeled so that they directly
relate to the video file's content. In order to ensure that your video or animation material is directly
usable, please provide the files in one of our recommended file formats with a preferred maximum
size of 50 MB. Video and animation files supplied will be published online in the electronic version
of your article in Elsevier Web products, including ScienceDirect: http://www.sciencedirect.com.
Please supply 'stills' with your files: you can choose any frame from the video or animation or
make a separate image. These will be used instead of standard icons and will personalize the
link to your video data. For more detailed instructions please visit our video instruction pages at
http://www.elsevier.com/artworkinstructions. Note: since video and animation cannot be embedded
in the print version of the journal, please provide text for both the electronic and the print version
for the portions of the article that refer to this content.
AudioSlides
The journal encourages authors to create an AudioSlides presentation with their published article.
AudioSlides are brief, webinar-style presentations that are shown next to the online article on
ScienceDirect. This gives authors the opportunity to summarize their research in their own words and
to help readers understand what the paper is about. More information and examples are available at
http://www.elsevier.com/audioslides. Authors of this journal will automatically receive an invitation
e-mail to create an AudioSlides presentation after acceptance of their paper.
Supplementary data
Elsevier accepts electronic supplementary material to support and enhance your scientific research.
Supplementary files offer the author additional possibilities to publish supporting applications, high-
resolution images, background datasets, sound clips and more. Supplementary files supplied will be
published online alongside the electronic version of your article in Elsevier Web products, including
ScienceDirect: http://www.sciencedirect.com. In order to ensure that your submitted material is
directly usable, please provide the data in one of our recommended file formats. Authors should
submit the material in electronic format together with the article and supply a concise and descriptive
caption for each file. For more detailed instructions please visit our artwork instruction pages at
http://www.elsevier.com/artworkinstructions.
3D neuroimaging
You can enrich your online articles by providing 3D neuroimaging data in NIfTI format. This will
be visualized for readers using the interactive viewer embedded within your article, and will enable
them to: browse through available neuroimaging datasets; zoom, rotate and pan the 3D brain
reconstruction; cut through the volume; change opacity and color mapping; switch between 3D and
2D projected views; and download the data. The viewer supports both single (.nii) and dual (.hdr
and .img) NIfTI file formats. Recommended size of a single uncompressed dataset is 100 MB or
less. Multiple datasets can be submitted. Each dataset will have to be zipped and uploaded to the
online submission system via the '3D neuroimaging data' submission category. Please provide a short
informative description for each dataset by filling in the 'Description' field when uploading a dataset.
Note: all datasets will be available for downloading from the online article on ScienceDirect. If you have
concerns about your data being downloadable, please provide a video instead. For more information
see: http://www.elsevier.com/3DNeuroimaging.
Submission checklist
The following list will be useful during the final checking of an article prior to sending it to the journal
for review. Please consult this Guide for Authors for further details of any item.
Ensure that the following items are present:
One author has been designated as the corresponding author with contact details:
• E-mail address
• Full postal address
• Telephone
All necessary files have been uploaded, and contain:
• Keywords
• All figure captions
• All tables (including title, description, footnotes)
Further considerations
• Manuscript has been 'spell-checked' and 'grammar-checked'
• All references mentioned in the Reference list are cited in the text, and vice versa
• Permission has been obtained for use of copyrighted material from other sources (including the Web)
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• Color figures are clearly marked as being intended for color reproduction on the Web (free of charge)
and in print, or to be reproduced in color on the Web (free of charge) and in black-and-white in print
• If only color on the Web is required, black-and-white versions of the figures are also supplied for
printing purposes
For any further information please visit our customer support site at http://support.elsevier.com.
AFTER ACCEPTANCE
Use of the Digital Object Identifier
The Digital Object Identifier (DOI) may be used to cite and link to electronic documents. The DOI
consists of a unique alpha-numeric character string which is assigned to a document by the publisher
upon the initial electronic publication. The assigned DOI never changes. Therefore, it is an ideal
medium for citing a document, particularly 'Articles in press' because they have not yet received their
full bibliographic information. Example of a correctly given DOI (in URL format; here an article in the
journal Physics Letters B):
http://dx.doi.org/10.1016/j.physletb.2010.09.059
When you use a DOI to create links to documents on the web, the DOIs are guaranteed never to
change.
Online proof correction
Corresponding authors will receive an e-mail with a link to our ProofCentral system, allowing
annotation and correction of proofs online. The environment is similar to MS Word: in addition to
editing text, you can also comment on figures/tables and answer questions from the Copy Editor.
Web-based proofing provides a faster and less error-prone process by allowing you to directly type
your corrections, eliminating the potential introduction of errors.
If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions
for proofing will be given in the e-mail we send to authors, including alternative methods to the online
version and PDF.
We will do everything possible to get your article published quickly and accurately - please upload
all of your corrections within 48 hours. It is important to ensure that all corrections are sent back
to us in one communication. Please check carefully before replying, as inclusion of any subsequent
corrections cannot be guaranteed. Proofreading is solely your responsibility. Note that Elsevier may
proceed with the publication of your article if no response is received.
Offprints
The corresponding author, at no cost, will be provided with a PDF file of the article via e-
mail (the PDF file is a watermarked version of the published article and includes a cover sheet
with the journal cover image and a disclaimer outlining the terms and conditions of use). For
an extra charge, paper offprints can be ordered via the offprint order form which is sent once
the article is accepted for publication. Both corresponding and co-authors may order offprints
at any time via Elsevier's WebShop (http://webshop.elsevier.com/myarticleservices/offprints).
Authors requiring printed copies of multiple articles may use Elsevier WebShop's
'Create Your Own Book' service to collate multiple articles within a single cover
(http://webshop.elsevier.com/myarticleservices/offprints/myarticlesservices/booklets).
AUTHOR INQUIRIES
For inquiries relating to the submission of articles (including electronic submission) please visit
this journal's homepage. For detailed instructions on the preparation of electronic artwork,
please visit http://www.elsevier.com/artworkinstructions. Contact details for questions arising after
acceptance of an article, especially those relating to proofs, will be provided by the publisher.
You can track accepted articles at http://www.elsevier.com/trackarticle. You can also check
our Author FAQs at http://www.elsevier.com/authorFAQ and/or contact Customer Support via
http://support.elsevier.com.
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